Precision BioSciences to Report Third Quarter 2026 Financial Results on November 3, 2026
Business Wire•29/10/2026•07:01 ET
0
Key Highlights
- ➤Precision BioSciences (DTIL) will report Q3 2026 financial results November 3, 2026
- ➤Company will provide a business update alongside its third-quarter results
- ➤ARCUS platform supports clinical-stage in vivo gene-editing candidates for genetic and infectious diseases
Precision BioSciences to Report Third Quarter 2026 Financial Results on November 3, 2026
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it will publish financial results for the third quarter 2026 and provide a business update on Tuesday, November 3, 2026.
Get started
Create a free account to read the full story.